OncoMatch/Clinical Trials/NCT07030907
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Is NCT07030907 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies OPB-101 for ovarian cancer recurrent.
Treatment: OPB-101 — The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101. Participants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time treatment. Participants will be in the hospital when they receive OPB-101 and then be checked at the clinical site frequently for the first few months.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Allowed: BRCA1 germline or somatic mutation
Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1/2 mutation.
Allowed: BRCA2 germline or somatic mutation
Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1/2 mutation.
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
Received at least 2 prior lines of systemic chemotherapy including a platinum-based chemotherapy.
Cannot have received: radiotherapy
Exception: within 2 weeks of start of study intervention
Prior radiotherapy within 2 weeks of start of study intervention.
Cannot have received: chemotherapy
Exception: within the previous 3 weeks
Received chemotherapy within the previous 3 weeks.
Cannot have received: CAR-T cell therapy
Received prior CAR T cell therapy.
Cannot have received: mesothelin targeted therapy
Received prior mesothelin targeted therapy.
Cannot have received: investigational agents or tumor vaccines
Received investigational agents or tumor vaccines.
Lab requirements
Liver function
alkaline phosphatase ≤ 2.5 x uln
Cardiac function
lvef ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Karmanos Cancer Institute · Detroit, Michigan
- University of Minnesota · Minneapolis, Minnesota
- Roswell Park · Buffalo, New York
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07030907 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy, chemotherapy, CAR-T cell therapy disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages